CDK5 and medulloblastoma: Prior studies have shown that CDK5 enhances PD-L1 expression in medulloblastoma (11), and we have previously demonstrated that genetic knockdown of CDK5 or pharmacological inhibition with Roscovitine increases proteasomal degradation of PD-L1 leading to a reduction in PD-L1 expression in NSCLC (12).